Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

被引:370
作者
Doering, Gerd [1 ]
Flume, Patrick [2 ]
Heijerman, Harry [3 ]
Elborn, J. Stuart [4 ]
Angyalosi, G.
Assael, B.
Bell, S.
Bilton, D.
De Boeck, K.
Bush, A.
Campbell, P. W., III
Cattaneo, A.
Dembowsky, K.
Drevinek, P.
Dubois, C.
Eichler, I.
Elborn, J. S.
Flume, P. A.
Foweraker, J. E.
Gallagher, C.
Gartner, S.
Geller, D. E.
Goldman, M.
Goss, C. H.
Gupta, R.
Heijerman, H. G.
Henig, N.
Higgins, M.
Hjelte, L.
Hoiby, N.
Jongejan, R.
Knoch, M.
Konstan, M. W.
Muhlebach, M. S.
Nieuwenhuizen, P. W.
Parkins, M. D.
Pressler, T.
Quittner, A. L.
Ratjen, F.
Ramsey, B. W.
Smyth, A.
Thieroff-Ekerdt, R.
Tullis, E.
van der Ent, C. K.
Vazquez, C.
Wainwright, C. E.
机构
[1] Univ Tubingen, Inst Med Microbiol & Hyg, D-72074 Tubingen, Germany
[2] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[3] Ziekenhuis Leyenburg, Dept Pathol, NL-2545 CH The Hague, Netherlands
[4] Queens Univ, Ctr Infect & Immun, Belfast BT9 7AB, Antrim, North Ireland
关键词
PSEUDOMONAS-AERUGINOSA INFECTION; RESISTANT STAPHYLOCOCCUS-AUREUS; INHALED AZTREONAM LYSINE; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; TOBRAMYCIN INHALATION POWDER; YOUNG-CHILDREN; PULMONARY-FUNCTION; DOUBLE-BLIND; STENOTROPHOMONAS-MALTOPHILIA; FEV1; DECLINE;
D O I
10.1016/j.jcf.2012.10.004
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the Major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed. (C) 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:461 / 479
页数:19
相关论文
共 173 条
[1]   Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial [J].
Aaron, SD ;
Vandemheen, KL ;
Ferris, W ;
Fergusson, D ;
Tullis, E ;
Haase, D ;
Berthiaume, Y ;
Brown, N ;
Wilcox, P ;
Yazghatlian, V ;
Bye, P ;
Bell, S ;
Chan, F ;
Rose, B ;
Jeanneret, A ;
Stephenson, A ;
Noseworthy, M ;
Freitag, A ;
Paterson, N ;
Doucette, S ;
Harbour, C ;
Ruel, M ;
MacDonald, N .
LANCET, 2005, 366 (9484) :463-471
[2]   Measuring health-related quality of life in clinical trials in cystic fibrosis [J].
Abbott, J. ;
Hart, A. ;
Havermans, T. ;
Matossian, A. ;
Goldbeck, L. ;
Barreto, C. ;
Bergsten-Brucefors, A. ;
Besier, T. ;
Catastini, P. ;
Lupi, F. ;
Staab, D. .
JOURNAL OF CYSTIC FIBROSIS, 2011, 10 :S82-S85
[3]   Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis [J].
Amadori, Anna ;
Antonelli, Andrea ;
Balteri, Ilaria ;
Schreiber, Anja ;
Bugiani, Massimiliano ;
De Rose, Virginia .
RESPIRATORY MEDICINE, 2009, 103 (03) :407-413
[4]   The Effect of Early Pseudomonas aeruginosa Treatment on Lung Function in Pediatric Cystic Fibrosis [J].
Amin, Reshma ;
Lam, Michelle ;
Dupuis, Annie ;
Ratjen, Felix .
PEDIATRIC PULMONOLOGY, 2011, 46 (06) :554-558
[5]  
Annemans L, 2011, HLTH EC NONECONOMICS
[6]  
[Anonymous], GUID ECFSPR
[7]  
[Anonymous], 2009, CHMP GUID CLIN DEV M
[8]  
[Anonymous], GUID METH TECHN APPR
[9]  
[Anonymous], 2010, Cystic fibrosis foundation patient registry 2020 annual data report
[10]  
Anstead M, J CYST FIBR IN PRESS